World Health Organization, South-East Asia Regional Office
Vol. 21, Week 52, 2017
Published 2 January 2018
Meetings/ Important events:
Regional Working Group Meeting on Immunization, New Delhi, India, 28-30 January 2018
Lessons from the Big Six- Closing the Immunity Gap for Measles Elimination and Rubella/ CRS control, New Delhi, India, 31 January-02
February 2018
Table 1: Measles & Rubella Laboratory Supported Case-based Surveillance Performance Indicators by Country, 2017* (data as of 2 January 2018)
Case classification (number)
Pending classification
Epidemiologicallyconfirmed
Reporti ng
% di s tri cts
ra te of
reporti ng a t
di s ca rded
Mea s l es
Rubel l a
l ea s t
non2 di s ca rded i nci dence 1 i nci dence 2
mea s l es
nonper
per
non-rubel l a
mea s l es
mi l l i on
mi l l i on
ca s es a t the
n
non-rubel l a
pop
pop n
na ti ona l
ca s es per
l evel per
n
100,000 pop
100,000 pop n
Laboratory-confirmed
Discarded non-measles nonrubella cases
Rubel l a
Clinically-confirmed
% s erol ogy
res ul ts
reported
w/i n 4 da ys
of
s peci men
recei ved a t
l a bora tory
Mea s l es
Epidemiologicallyconfirmed
Number of
s erum
s peci mens
recei ved i n
l a bora tory
% s erum
s peci mens
recei ved a t
l a bora tory
w/i n 5
da ys of
col l ecti on
%
s peci mens
tes ted for
s erol ogy
of
s peci mens
recei ved
i n the
l a bora tory
Laboratory-confirmed
%
s us pected
%
ca s es wi th
Number of a dequa te s us pected
s us pected i nves ti ga ti ca s es wi th
mea s l es
s erum
on
ca s es
i ni ti a ted s peci mens
col l ected
w/i n 48
hours of
noti fi ca ti on
8,048
92
80
6,421
100
100
63
2,649
961
509
222
58
3,649
0
2.34
75
26.40
Bhutan
221
84
79
166
59
105
46
14
0
0
2
0
160
45
21.47
65
18.79
2.68
DPR Korea
105
100
100
105
100
100
99
0
0
0
0
0
105
0
0.42
0.00
0.00
Countries
Bangladesh
India 3
19,013
0
32
5,974
81
87
60
2,944
6,154
0
733
2,003
2,692
4,487
0.21
4,946
47
100
2,468
93
73
27
662
0
0
343
0
342
3,599
0.14
Maldives
63
97
100
63
100
100
70
1
0
0
1
0
59
2
17.26
60
2.93
2.93
Myanmar
1,661
40
88
1,459
99
100
94
1,000
179
71
3
0
377
31
0.73
14
24.31
0.06
Nepal
897
23
89
386
64
190
68
57
25
11
16
0
711
77
2.60
55
3.41
0.59
Sri Lanka
203
98
89
177
90
100
62
1
0
18
1
0
183
0
0.89
23
62.00
0.42
Thailand
2,834
29
88
2,390
58
95
59
1,426
14
453
24
0
825
92
1.27
127
100
99
119
100
72
52
0
0
0
3
0
120
4
9.90
38,118
32
60
19,728
87
94
59
8,754
7,333
1,062
1,348
2,061
9,223
8,337
0.49
Indonesia
4
Timor-Leste
SEAR
1
Includes labo rato ry-co nfirmed, epidemio lo gically-linked and clinically-co nfirmed measles cases
2
Includes labo rato ry-co nfirmed and epidemio lo gically-linked rubella cases
4
5
1.79
38
A lso includes the cases fro m enhanced measles case-based surveillance.
7.19
2.16
2.63
1.36
29.18
0.37
0.00
2.48
9.20
1.83
ND=No data
3 Cases fro m suspected measles o utbreak investigatio n o nly, case based surveillance is gradually exCA nding in the co untry
* Figures in the table 1 are restricted to availability of various dates required for calculation. Thus they may not adequately reflect cases with missing dates for various timelines.
Table 2: Measles & Rubella Laboratory Supported Case-based Surveillance Performance Indicators by Country, 2016* (data as of 2 January 2018)
Case classification (number)
Pending classification
Discarded non-measles nonrubella cases
Epidemiologicallyconfirmed
Reporti ng
% di s tri cts
ra te of
reporti ng a t
di s ca rded
Mea s l es
Rubel l a
l ea s t
non2 di s ca rded i nci dence 1 i nci dence 2
mea s l es
nonper
per
non-rubel l a
mea s l es
mi l l i on
mi l l i on
ca s es a t the
n
n
non-rubel l a
pop
pop
na ti ona l
ca s es per
l evel per
n
100,000 pop
100,000 pop n
Laboratory-confirmed
DPR Korea
Rubel l a
Clinically-confirmed
Bhutan
% s erol ogy
res ul ts
reported
w/i n 4 da ys
of
s peci men
recei ved a t
l a bora tory
Epidemiologicallyconfirmed
Bangladesh
Number of
s erum
s peci mens
recei ved i n
l a bora tory
%
% s erum s peci mens
s peci mens tes ted for
recei ved a t s erol ogy
of
l a bora tory
w/i n 5 s peci mens
recei ved
da ys of
i n the
col l ecti on
l a bora tory
Mea s l es
Laboratory-confirmed
Countries
%
s us pected
%
ca s es wi th
Number of a dequa te s us pected
s us pected i nves ti ga ti ca s es wi th
s erum
on
mea s l es
i ni ti a ted s peci mens
ca s es
col l ected
w/i n 48
hours of
noti fi ca ti on
4 298
94
87
3 732
100
100
92
619
354
96
165
0
3 064
0
1.96
80
6.85
1.06
149
63
87
127
59
102
47
10
0
0
0
0
60
79
8.05
55
13.42
0.00
0.00
0.00
3
12.93
7.18
11.25
4.65
73
100
100
73
100
100
100
0
0
0
0
0
66
7
0.27
41 350
0
22
9 022
84
83
31
3 649
12 713
0
1 618
7 466
6 989
9 018
0.55
8 065
44
100
5 856
98
84
32
2 837
0
0
1 172
0
2 402
1 652
0.95
Maldives
11
100
100
11
100
0
0
0
0
0
0
0
11
0
3.22
15
0.00
0.00
Myanmar
587
0
86
503
100
99
97
194
59
21
10
0
303
0
0.59
11
5.33
0.19
1 079
13
82
1
100
0
137
102
31
22
0
772
15
2.83
56
9.89
0.81
Sri Lanka
339
63
86
291
88
100
68
64
0
48
1
0
226
0
1.09
27
62.00
0.42
Thailand
1 431
25
87
1 096
61
99
58
695
15
239
7
0
415
60
0.64
14.63
0.11
122
75
91
111
100
95
63
2
0
11
9
0
100
0
8.25
10.73
7.43
57 504
15
42
20 823
90
92
46
8 207
13 243
446
3 004
7 466
14 408
10 831
0.77
11.74
5.61
India 3
Indonesia
Nepal
4
5
Timor-Leste
SEAR
1
Includes labo rato ry-co nfirmed, epidemio lo gically-linked and clinically-co nfirmed measles cases
4
A lso includes the cases fro m enhanced measles case-based surveillance.
2
Includes labo rato ry-co nfirmed and epidemio lo gically-linked rubella cases
5
So me Lab data variables no t available.
46
ND=No data
3 Cases fro m suspected measles o utbreak investigatio n o nly, case based surveillance is gradually exCA nding in the co untry
* Figures in the table 2 are restricted to availability of various dates required for calculation. Thus they may not adequately reflect cases with missing dates for various timelines.
Data Sources: Ministries of Health in SEAR Countries.
Published by Immunization & Vaccine Development, World Health Organization, Regional Office for South-East Asia, New Delhi – 110002, India
Tel: 91-11-2337-0804 / 91-11-4304-0000 Fax: 91-11-2337-0251 / 0106 E-mail: SearEpidata@who.int, URL:
Vol. 21,
Week 52, 2017
Vaccine Preventable Disease Surveillance Bulletin
Page 2
Table 3: Classification of AFP Cases and Key Surveillance Indicators, 2016-2017 (data as of 2 January 2018)
2016 (Onset)
2017 (Onset)
AFP
Surveillance Indicators
1
2
Case Classification 1
Total
>90 Days 3
0
0
2.85
2.85
99
100
1,356
0
0
0
1,281
75
14
2.72
2.57
98
99
11
0
0
5.11
5.11
73
100
8
0
0
0
7
1
0
3.24
2.83
88
100
DPR Korea
105
0
0
0
105
0
0
1.83
1.83
98
100
103
0
0
0
65
38
17
1.80
1.14
96
99
Non-Polio AFP Rate
AFP Rate
4
Vaccine Derived
Poliovirus Cases
Non-Polio AFP Rate
AFP Rate
>90 Days 3
Total
Vaccine Derived
Poliovirus Cases
AFP Cases
% with any specimen
Discarded (Non-polio
AFP)
1,437
0
Pending
% with 2 spec., at least
24 hrs apart, w/in 14
days
Compatible
0
0
Wild Poliovirus Cases
0
0
Pending
% with 2 spec., at least
24 hrs apart, w/in 14
days
0
11
Bangladesh
4
1,437
Bhutan
Country
Wild Poliovirus Cases
AFP Cases
Specim en
% with any specimen
Specim en
Discarded (Non-polio
AFP)
AFP Rates
Surveillance Indicators
Annualized
AFP Rates 2
Compatible
Case Classification
AFP
India
46,500
0
1
15
46,484
0
0
10.60 10.60
87
98
37,646
0
0
12
34,596 3,038 1,191
8.59
7.89
86
98
Indonesia
1,409
0
0
0
1,409
0
0
2.01
2.01
86
96
1,441
0
0
1
1,214
226
122
2.05
1.73
83
97
Maldives
2
0
0
0
2
0
0
2.11
2.11
0
100
6
0
0
0
4
2
0
6.34
4.23
67
100
Myanm ar
466
0
0
0
466
0
0
3.38
3.38
96
100
360
0
0
0
310
50
2
2.67
2.30
96
100
Nepal
455
0
0
0
455
0
0
5.24
5.24
96
100
342
0
0
0
326
16
2
3.94
3.76
99
100
Sri Lanka
65
0
0
0
65
0
0
1.20
1.20
85
98
69
0
0
0
65
4
0
1.27
1.20
84
99
Thailand
246
0
0
0
246
0
0
2.04
2.04
75
98
171
0
0
0
130
41
25
1.48
1.12
65
92
Tim or-Leste
10
0
0
0
10
0
0
2.16
2.16
50
80
3
0
0
0
1
2
1
0.65
0.22
33
100
50,706
0
1
15
50,690
0
0
8.38
8.38
87
98
41,505
0
0
13
6.87
6.29
86
98
SEAR
37,999 3,493 1,374
1
All countries are using the virologic classification scheme.
2
AFP rates per 100,000 children aged 15 years of age or missing age information are excluded).
3
90 days calculation based on date of paralysis onset subtracted from date of last report received from member countries by SEARO.
2016 India: One type 2 VDPV (iVDPV=1)
[a=ambiguous c=circulating i=immunodeficiency]
4
Table 4: Intratypic Differentiation (ITD) of Isolates from AFP Cases, 2016-2017 (data as of 2 January 2018)
0
0
1
3
0
0
1
0
0
20
0
0
0
0
0
0
0
0
0
0
DPR Korea
NPL, Pyongyong
India
0
0
0
0
0
Vaccine
mixture
NPEV by
PCR
0
8
0
0
0
0
7
5
7
Days days
0
BJMC, Ahmedabad
258
0
78
0
25
0
0
74
80
1
0
0
0
0
227
0
78
0
0
0
0
66
76
7
0
0
0
0
NIV, Bengaluru
225
0
56
0
24
0
0
67
70
6
2
0
0
0
151
0
57
0
0
0
0
35
45
14
0
0
0
0
ERC, Mumbai
172
0
53
0
13
0
0
52
43
11
0
0
0
0
154
0
52
0
0
0
0
45
36
21
0
0
0
0
SGPGI, Lucknow
311
0
56
0
53
0
0
86
66
16
34
0
0
0
289
0
60
0
0
0
0
100
63
25
41
0
0
0
KIPM, Chennai
98
0
26
0
17
1
0
26
28
0
0
0
0
0
48
0
9
0
0
0
0
27
12
0
0
0
0
0
NCDC, Delhi
231
0
47
0
38
0
0
91
52
3
0
0
0
0
204
0
58
0
0
0
0
87
51
8
0
0
0
0
IoS, Kolkatta
113
0
26
0
18
0
0
35
33
0
1
0
0
0
170
0
54
0
0
0
0
39
57
17
3
0
0
0
CRI, Kasauli
35
0
5
0
7
0
0
11
12
0
0
0
0
0
21
0
11
0
0
0
0
6
4
0
0
0
0
0
1,443
0
347
0
195
1
0
442
384
37
37
0
0
0
1,264
0
379
0
0
0
0
92
44
0
0
0
India Total
Indonesia
0
Negative
0
1
Results
pending
NEV
0
0
Vaccine
3
0
Wild
0
0
VDPV
8
1
Vaccine
IPH, Dhaka
NIH, Bangkok
Wild
Bangladesh
Bhutan
Vaccine
7
Days days
Intratypic Differentiation results
Polio 1
Polio 2
Polio 3
Wild
Results
pending
AFP cases
referred
for ITD
NEV
Negative
2017
Vaccine
mixture
NPEV by
PCR
Vaccine
Wild
VDPV
Vaccine
Wild
Vaccine
ITD Labs
Wild
Country of
Case
AFP cases
referred
for ITD
2016
Intratypic Differentiation results
Polio 1
Polio 2
Polio 3
405 344
Bio Farma, Bandung
18
0
9
0
3
0
0
1
5
0
0
0
0
0
2
0
0
0
0
0
0
2
0
0
0
0
0
0
NIHRD, Jakarta
12
0
4
0
0
0
0
5
3
0
0
0
0
0
2
0
0
0
0
0
0
0
2
0
0
0
0
0
PHL, Surabaya
13
0
2
0
4
0
0
4
3
0
0
0
0
0
1
0
0
0
0
0
0
1
0
0
0
0
0
0
43
0
15
0
7
0
0
10
11
0
0
0
0
0
5
0
0
0
0
0
0
3
2
0
0
0
0
0
Indonesia Total
Myanmar
NHL, Yangon
7
0
1
0
1
0
0
2
3
0
0
0
0
0
6
0
1
0
0
0
0
4
1
0
0
0
0
0
Nepal
NIH, Bangkok
6
0
2
0
2
0
0
1
1
0
0
0
0
0
5
0
0
0
0
0
0
3
2
0
0
0
0
0
Sri Lanka
MRI, Colombo
1
0
0
0
0
0
0
1
0
0
0
0
0
0
0
Thailand
NIH, Bangkok
4
0
0
0
0
0
0
2
2
0
0
0
0
0
5
0
2
0
0
0
0
3
0
1,513
0
368
0
206
1
0
459
404
37
37
1
0
0
1,305
0
390
0
0
0
0
TOTAL
425 354
0
0
0
0
0
92
44
0
0
0
Published 2 January 2018
Meetings/ Important events:
Regional Working Group Meeting on Immunization, New Delhi, India, 28-30 January 2018
Lessons from the Big Six- Closing the Immunity Gap for Measles Elimination and Rubella/ CRS control, New Delhi, India, 31 January-02
February 2018
Table 1: Measles & Rubella Laboratory Supported Case-based Surveillance Performance Indicators by Country, 2017* (data as of 2 January 2018)
Case classification (number)
Pending classification
Epidemiologicallyconfirmed
Reporti ng
% di s tri cts
ra te of
reporti ng a t
di s ca rded
Mea s l es
Rubel l a
l ea s t
non2 di s ca rded i nci dence 1 i nci dence 2
mea s l es
nonper
per
non-rubel l a
mea s l es
mi l l i on
mi l l i on
ca s es a t the
n
non-rubel l a
pop
pop n
na ti ona l
ca s es per
l evel per
n
100,000 pop
100,000 pop n
Laboratory-confirmed
Discarded non-measles nonrubella cases
Rubel l a
Clinically-confirmed
% s erol ogy
res ul ts
reported
w/i n 4 da ys
of
s peci men
recei ved a t
l a bora tory
Mea s l es
Epidemiologicallyconfirmed
Number of
s erum
s peci mens
recei ved i n
l a bora tory
% s erum
s peci mens
recei ved a t
l a bora tory
w/i n 5
da ys of
col l ecti on
%
s peci mens
tes ted for
s erol ogy
of
s peci mens
recei ved
i n the
l a bora tory
Laboratory-confirmed
%
s us pected
%
ca s es wi th
Number of a dequa te s us pected
s us pected i nves ti ga ti ca s es wi th
mea s l es
s erum
on
ca s es
i ni ti a ted s peci mens
col l ected
w/i n 48
hours of
noti fi ca ti on
8,048
92
80
6,421
100
100
63
2,649
961
509
222
58
3,649
0
2.34
75
26.40
Bhutan
221
84
79
166
59
105
46
14
0
0
2
0
160
45
21.47
65
18.79
2.68
DPR Korea
105
100
100
105
100
100
99
0
0
0
0
0
105
0
0.42
0.00
0.00
Countries
Bangladesh
India 3
19,013
0
32
5,974
81
87
60
2,944
6,154
0
733
2,003
2,692
4,487
0.21
4,946
47
100
2,468
93
73
27
662
0
0
343
0
342
3,599
0.14
Maldives
63
97
100
63
100
100
70
1
0
0
1
0
59
2
17.26
60
2.93
2.93
Myanmar
1,661
40
88
1,459
99
100
94
1,000
179
71
3
0
377
31
0.73
14
24.31
0.06
Nepal
897
23
89
386
64
190
68
57
25
11
16
0
711
77
2.60
55
3.41
0.59
Sri Lanka
203
98
89
177
90
100
62
1
0
18
1
0
183
0
0.89
23
62.00
0.42
Thailand
2,834
29
88
2,390
58
95
59
1,426
14
453
24
0
825
92
1.27
127
100
99
119
100
72
52
0
0
0
3
0
120
4
9.90
38,118
32
60
19,728
87
94
59
8,754
7,333
1,062
1,348
2,061
9,223
8,337
0.49
Indonesia
4
Timor-Leste
SEAR
1
Includes labo rato ry-co nfirmed, epidemio lo gically-linked and clinically-co nfirmed measles cases
2
Includes labo rato ry-co nfirmed and epidemio lo gically-linked rubella cases
4
5
1.79
38
A lso includes the cases fro m enhanced measles case-based surveillance.
7.19
2.16
2.63
1.36
29.18
0.37
0.00
2.48
9.20
1.83
ND=No data
3 Cases fro m suspected measles o utbreak investigatio n o nly, case based surveillance is gradually exCA nding in the co untry
* Figures in the table 1 are restricted to availability of various dates required for calculation. Thus they may not adequately reflect cases with missing dates for various timelines.
Table 2: Measles & Rubella Laboratory Supported Case-based Surveillance Performance Indicators by Country, 2016* (data as of 2 January 2018)
Case classification (number)
Pending classification
Discarded non-measles nonrubella cases
Epidemiologicallyconfirmed
Reporti ng
% di s tri cts
ra te of
reporti ng a t
di s ca rded
Mea s l es
Rubel l a
l ea s t
non2 di s ca rded i nci dence 1 i nci dence 2
mea s l es
nonper
per
non-rubel l a
mea s l es
mi l l i on
mi l l i on
ca s es a t the
n
n
non-rubel l a
pop
pop
na ti ona l
ca s es per
l evel per
n
100,000 pop
100,000 pop n
Laboratory-confirmed
DPR Korea
Rubel l a
Clinically-confirmed
Bhutan
% s erol ogy
res ul ts
reported
w/i n 4 da ys
of
s peci men
recei ved a t
l a bora tory
Epidemiologicallyconfirmed
Bangladesh
Number of
s erum
s peci mens
recei ved i n
l a bora tory
%
% s erum s peci mens
s peci mens tes ted for
recei ved a t s erol ogy
of
l a bora tory
w/i n 5 s peci mens
recei ved
da ys of
i n the
col l ecti on
l a bora tory
Mea s l es
Laboratory-confirmed
Countries
%
s us pected
%
ca s es wi th
Number of a dequa te s us pected
s us pected i nves ti ga ti ca s es wi th
s erum
on
mea s l es
i ni ti a ted s peci mens
ca s es
col l ected
w/i n 48
hours of
noti fi ca ti on
4 298
94
87
3 732
100
100
92
619
354
96
165
0
3 064
0
1.96
80
6.85
1.06
149
63
87
127
59
102
47
10
0
0
0
0
60
79
8.05
55
13.42
0.00
0.00
0.00
3
12.93
7.18
11.25
4.65
73
100
100
73
100
100
100
0
0
0
0
0
66
7
0.27
41 350
0
22
9 022
84
83
31
3 649
12 713
0
1 618
7 466
6 989
9 018
0.55
8 065
44
100
5 856
98
84
32
2 837
0
0
1 172
0
2 402
1 652
0.95
Maldives
11
100
100
11
100
0
0
0
0
0
0
0
11
0
3.22
15
0.00
0.00
Myanmar
587
0
86
503
100
99
97
194
59
21
10
0
303
0
0.59
11
5.33
0.19
1 079
13
82
1
100
0
137
102
31
22
0
772
15
2.83
56
9.89
0.81
Sri Lanka
339
63
86
291
88
100
68
64
0
48
1
0
226
0
1.09
27
62.00
0.42
Thailand
1 431
25
87
1 096
61
99
58
695
15
239
7
0
415
60
0.64
14.63
0.11
122
75
91
111
100
95
63
2
0
11
9
0
100
0
8.25
10.73
7.43
57 504
15
42
20 823
90
92
46
8 207
13 243
446
3 004
7 466
14 408
10 831
0.77
11.74
5.61
India 3
Indonesia
Nepal
4
5
Timor-Leste
SEAR
1
Includes labo rato ry-co nfirmed, epidemio lo gically-linked and clinically-co nfirmed measles cases
4
A lso includes the cases fro m enhanced measles case-based surveillance.
2
Includes labo rato ry-co nfirmed and epidemio lo gically-linked rubella cases
5
So me Lab data variables no t available.
46
ND=No data
3 Cases fro m suspected measles o utbreak investigatio n o nly, case based surveillance is gradually exCA nding in the co untry
* Figures in the table 2 are restricted to availability of various dates required for calculation. Thus they may not adequately reflect cases with missing dates for various timelines.
Data Sources: Ministries of Health in SEAR Countries.
Published by Immunization & Vaccine Development, World Health Organization, Regional Office for South-East Asia, New Delhi – 110002, India
Tel: 91-11-2337-0804 / 91-11-4304-0000 Fax: 91-11-2337-0251 / 0106 E-mail: SearEpidata@who.int, URL:
Vol. 21,
Week 52, 2017
Vaccine Preventable Disease Surveillance Bulletin
Page 2
Table 3: Classification of AFP Cases and Key Surveillance Indicators, 2016-2017 (data as of 2 January 2018)
2016 (Onset)
2017 (Onset)
AFP
Surveillance Indicators
1
2
Case Classification 1
Total
>90 Days 3
0
0
2.85
2.85
99
100
1,356
0
0
0
1,281
75
14
2.72
2.57
98
99
11
0
0
5.11
5.11
73
100
8
0
0
0
7
1
0
3.24
2.83
88
100
DPR Korea
105
0
0
0
105
0
0
1.83
1.83
98
100
103
0
0
0
65
38
17
1.80
1.14
96
99
Non-Polio AFP Rate
AFP Rate
4
Vaccine Derived
Poliovirus Cases
Non-Polio AFP Rate
AFP Rate
>90 Days 3
Total
Vaccine Derived
Poliovirus Cases
AFP Cases
% with any specimen
Discarded (Non-polio
AFP)
1,437
0
Pending
% with 2 spec., at least
24 hrs apart, w/in 14
days
Compatible
0
0
Wild Poliovirus Cases
0
0
Pending
% with 2 spec., at least
24 hrs apart, w/in 14
days
0
11
Bangladesh
4
1,437
Bhutan
Country
Wild Poliovirus Cases
AFP Cases
Specim en
% with any specimen
Specim en
Discarded (Non-polio
AFP)
AFP Rates
Surveillance Indicators
Annualized
AFP Rates 2
Compatible
Case Classification
AFP
India
46,500
0
1
15
46,484
0
0
10.60 10.60
87
98
37,646
0
0
12
34,596 3,038 1,191
8.59
7.89
86
98
Indonesia
1,409
0
0
0
1,409
0
0
2.01
2.01
86
96
1,441
0
0
1
1,214
226
122
2.05
1.73
83
97
Maldives
2
0
0
0
2
0
0
2.11
2.11
0
100
6
0
0
0
4
2
0
6.34
4.23
67
100
Myanm ar
466
0
0
0
466
0
0
3.38
3.38
96
100
360
0
0
0
310
50
2
2.67
2.30
96
100
Nepal
455
0
0
0
455
0
0
5.24
5.24
96
100
342
0
0
0
326
16
2
3.94
3.76
99
100
Sri Lanka
65
0
0
0
65
0
0
1.20
1.20
85
98
69
0
0
0
65
4
0
1.27
1.20
84
99
Thailand
246
0
0
0
246
0
0
2.04
2.04
75
98
171
0
0
0
130
41
25
1.48
1.12
65
92
Tim or-Leste
10
0
0
0
10
0
0
2.16
2.16
50
80
3
0
0
0
1
2
1
0.65
0.22
33
100
50,706
0
1
15
50,690
0
0
8.38
8.38
87
98
41,505
0
0
13
6.87
6.29
86
98
SEAR
37,999 3,493 1,374
1
All countries are using the virologic classification scheme.
2
AFP rates per 100,000 children aged 15 years of age or missing age information are excluded).
3
90 days calculation based on date of paralysis onset subtracted from date of last report received from member countries by SEARO.
2016 India: One type 2 VDPV (iVDPV=1)
[a=ambiguous c=circulating i=immunodeficiency]
4
Table 4: Intratypic Differentiation (ITD) of Isolates from AFP Cases, 2016-2017 (data as of 2 January 2018)
0
0
1
3
0
0
1
0
0
20
0
0
0
0
0
0
0
0
0
0
DPR Korea
NPL, Pyongyong
India
0
0
0
0
0
Vaccine
mixture
NPEV by
PCR
0
8
0
0
0
0
7
5
7
Days days
0
BJMC, Ahmedabad
258
0
78
0
25
0
0
74
80
1
0
0
0
0
227
0
78
0
0
0
0
66
76
7
0
0
0
0
NIV, Bengaluru
225
0
56
0
24
0
0
67
70
6
2
0
0
0
151
0
57
0
0
0
0
35
45
14
0
0
0
0
ERC, Mumbai
172
0
53
0
13
0
0
52
43
11
0
0
0
0
154
0
52
0
0
0
0
45
36
21
0
0
0
0
SGPGI, Lucknow
311
0
56
0
53
0
0
86
66
16
34
0
0
0
289
0
60
0
0
0
0
100
63
25
41
0
0
0
KIPM, Chennai
98
0
26
0
17
1
0
26
28
0
0
0
0
0
48
0
9
0
0
0
0
27
12
0
0
0
0
0
NCDC, Delhi
231
0
47
0
38
0
0
91
52
3
0
0
0
0
204
0
58
0
0
0
0
87
51
8
0
0
0
0
IoS, Kolkatta
113
0
26
0
18
0
0
35
33
0
1
0
0
0
170
0
54
0
0
0
0
39
57
17
3
0
0
0
CRI, Kasauli
35
0
5
0
7
0
0
11
12
0
0
0
0
0
21
0
11
0
0
0
0
6
4
0
0
0
0
0
1,443
0
347
0
195
1
0
442
384
37
37
0
0
0
1,264
0
379
0
0
0
0
92
44
0
0
0
India Total
Indonesia
0
Negative
0
1
Results
pending
NEV
0
0
Vaccine
3
0
Wild
0
0
VDPV
8
1
Vaccine
IPH, Dhaka
NIH, Bangkok
Wild
Bangladesh
Bhutan
Vaccine
7
Days days
Intratypic Differentiation results
Polio 1
Polio 2
Polio 3
Wild
Results
pending
AFP cases
referred
for ITD
NEV
Negative
2017
Vaccine
mixture
NPEV by
PCR
Vaccine
Wild
VDPV
Vaccine
Wild
Vaccine
ITD Labs
Wild
Country of
Case
AFP cases
referred
for ITD
2016
Intratypic Differentiation results
Polio 1
Polio 2
Polio 3
405 344
Bio Farma, Bandung
18
0
9
0
3
0
0
1
5
0
0
0
0
0
2
0
0
0
0
0
0
2
0
0
0
0
0
0
NIHRD, Jakarta
12
0
4
0
0
0
0
5
3
0
0
0
0
0
2
0
0
0
0
0
0
0
2
0
0
0
0
0
PHL, Surabaya
13
0
2
0
4
0
0
4
3
0
0
0
0
0
1
0
0
0
0
0
0
1
0
0
0
0
0
0
43
0
15
0
7
0
0
10
11
0
0
0
0
0
5
0
0
0
0
0
0
3
2
0
0
0
0
0
Indonesia Total
Myanmar
NHL, Yangon
7
0
1
0
1
0
0
2
3
0
0
0
0
0
6
0
1
0
0
0
0
4
1
0
0
0
0
0
Nepal
NIH, Bangkok
6
0
2
0
2
0
0
1
1
0
0
0
0
0
5
0
0
0
0
0
0
3
2
0
0
0
0
0
Sri Lanka
MRI, Colombo
1
0
0
0
0
0
0
1
0
0
0
0
0
0
0
Thailand
NIH, Bangkok
4
0
0
0
0
0
0
2
2
0
0
0
0
0
5
0
2
0
0
0
0
3
0
1,513
0
368
0
206
1
0
459
404
37
37
1
0
0
1,305
0
390
0
0
0
0
TOTAL
425 354
0
0
0
0
0
92
44
0
0
0